On the macrophage axis, innate immune agonists such as STING and TLR agonists are being explored to repolarize TAMs and induce type I interferon responses, which may also support NK cell activation and promote an inflamed tumour microenvironment. The gene discussed is STING1; the disease is neoplasm.